Literature DB >> 32113935

Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer.

Qi Chen1, Tao Wei1, Jianxin Wang1, Qi Zhang1, Jin Li1, Jingying Zhang2, Lei Ni1, Yi Wang1, Xueli Bai1, Tingbo Liang3.   

Abstract

OBJECTIVES: To establish and evaluate a first generation patient-derived xenograft (PDX) model in nude mice using tumors resected from pancreatic cancer (PC) patients for the identification of key factors that influence xenograft success and prediction of patient prognosis.
METHODS: Primary tumor samples harvested from PC patients who underwent curative resection between May 2016 and April 2018 at our hospital were xenografted into nude mice. Tumor size was evaluated for 2 months. Patients' baseline characteristics and follow-up data were analyzed.
RESULTS: Tumor xenograft models were generated from 67 patients; 30 (44.8%) were successful and 37 (55.2%) failed. Xenograft models could recapitulate the pathology and genetic information of the primary tumors. Univariate analysis identified tumor engraftment, post-operation CA19-9, tumor size, lymph node status, and lymphovascular invasion as significant predictors (P=0.000, 0.023, 0.004, 0.035 and 0.005, respectively) of disease-free survival (DFS). Multivariate Cox regression analysis confirmed tumor engraftment, tumor size and lymphovascular invasion function as independent risk factors for DFS (P=0.000, 0.039 and 0.025, respectively). The hazard ratio of tumor engraftment for DFS was 0.239 (95% confidence interval, 0.109 to 0.524). Kaplan-Meier analysis of DFS indicated an unfavorable outcome in the engraftment group compared to that in the failed engraftment group (6.2 vs. 12.2 months, log rank P=0.000).
CONCLUSION: The pathology and genetic information of primary PC tumors are recapitulated in the PDX tumor model in nude mice. Furthermore, engraftment success is an effective predictor of disease recurrence in patients after surgery.
Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CA19-9; Engraftment; PDX models; Pancreatic cancer; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 32113935     DOI: 10.1016/j.pan.2020.02.008

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

Review 1.  Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review.

Authors:  Tomohito Tanaka; Ruri Nishie; Shoko Ueda; Shunsuke Miyamoto; Sousuke Hashida; Hiromi Konishi; Shinichi Terada; Yuhei Kogata; Hiroshi Sasaki; Satoshi Tsunetoh; Kohei Taniguchi; Kazumasa Komura; Masahide Ohmichi
Journal:  J Clin Med       Date:  2022-05-06       Impact factor: 4.964

2.  Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.

Authors:  Yazhou Wang; Huahu Guo; Zhengkui Zhang; Qi Wang; Xiaodong Tian; Yinmo Yang
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.

Authors:  Patrick L Garcia; Aubrey L Miller; Karina J Yoon
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

4.  Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models.

Authors:  Ha-Yeon Shin; Eun-Ju Lee; Wookyeom Yang; Hyo Sun Kim; Dawn Chung; Hanbyoul Cho; Jae-Hoon Kim
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

Review 5.  Patient-derived xenografts as compatible models for precision oncology.

Authors:  Sung-Yup Cho
Journal:  Lab Anim Res       Date:  2020-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.